recombinant cd40l protein  (R&D Systems)

Journal: Vaccines

Article Title: CD8+ T Cells Primed by Antigenic Peptide-Pulsed B Cells or Dendritic Cells Generate Similar Anti-Tumor Response

doi: 10.3390/vaccines13090953

Figure Lengend Snippet: Epitope-specific priming of CD8+ T cells by B cells and DCs resulted in different activation marker expression profiles. B cells and DCs isolated from the C57Bl/6 spleen were either LPS treated or not and then loaded with SIINFEKL peptide. After 48 h of incubation with CD8+ T cells in the presence or absence of GM-CSF and IL-4, flow cytometry was performed to measure the expression of activation markers ( A ) 4-1BB, ( B ) CD25, ( C ) CD27, ( D ) CD28, ( E ) CD40L, ( F ) FASR, ( G ) CD69, ( H ) Ki67, ( I ) OX40, and ( J ) ICOS. Median fluorescence intensities (MFI) were plotted with mean and standard deviation. The percentage of CD8+ T cells positive for the expression of the respective cell surface markers are shown in . Each treatment group was tested with five biological replicates and each data point on the plot represents a biological replicate. Asterisks * indicate p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001. Results are representative of at least two similar, independent experiments.

Article Snippet: Recombinant mouse CD40L (Cat.# 8230-CL-050/CF) was purchased from R&D systems (Minneapolis, MN, USA).

Techniques: Activation Assay, Marker, Expressing, Isolation, Incubation, Flow Cytometry, Fluorescence, Standard Deviation